CRISPR Therapeutics AG (NASDAQ: CRSP) is -17.05% lower on its value in year-to-date trading and has touched a low of $32.19 and a high of $67.88 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CRSP stock was last observed hovering at around $32.66 in the last trading session, with the day’s loss setting it -0.01%.
Currently trading at $32.65, the stock is -16.90% and -22.31% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.07 million and changing -0.03% at the moment leaves the stock -30.55% off its SMA200. CRSP registered -49.46% loss for a year compared to 6-month loss of -28.57%. The firm has a 50-day simple moving average (SMA 50) of $42.0266 and a 200-day simple moving average (SMA200) of $47.009426.
The stock witnessed a -24.61% gain in the last 1 month and extending the period to 3 months gives it a -21.19%, and is -11.73% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.55% over the week and 5.15% over the month.
CRISPR Therapeutics AG (CRSP) has around 393 employees, a market worth around $2.81B and $37.31M in sales. Profit margin for the company is -981.54%. Distance from 52-week low is 1.43% and -51.90% from its 52-week high. The company has generated returns on investments over the last 12 months (-17.13%).
with sales reaching $6.39M over the same period.The EPS is expected to shrink by -9.43% this year, but quarterly earnings will post 65.54% year-over-year. Quarterly sales are estimated to grow 1,168.01% in year-over-year returns.
CRISPR Therapeutics AG (CRSP) Top Institutional Holders
546.0 institutions hold shares in CRISPR Therapeutics AG (CRSP), with institutional investors hold 79.09% of the company’s shares. The shares outstanding are 85.74M, and float is at 82.06M with Short Float at 24.75%. Institutions hold 77.78% of the Float.
The top institutional shareholder in the company is CAPITAL INTERNATIONAL INVESTORS with over 7.87 million shares valued at $424.8 million. The investor’s holdings represent 9.2619% of the CRSP Shares outstanding. As of 2024-06-30, the second largest holder is ARK INVESTMENT MANAGEMENT LLC with 7.78 million shares valued at $420.12 million to account for 9.1597 of the shares outstanding. The other top investors are SUMITOMO MITSUI TRUST HOLDINGS, INC. which holds 3.15 million shares representing 3.7111% and valued at over $170.21 million, while NIKKO ASSET MANAGEMENT AMERICAS, INC. holds 3.7111 of the shares totaling 3.15 million with a market value of $169.99 million.
CRISPR Therapeutics AG (CRSP) Insider Activity
The most recent transaction is an insider sale by Kulkarni Samarth, the company’s Chief Executive Officer. SEC filings show that Kulkarni Samarth sold 10,031 shares of the company’s common stock on Mar 21 ’25 at a price of $41.23 per share for a total of $0.41 million. Following the sale, the insider now owns 0.2 million shares.
CRISPR Therapeutics AG disclosed in a document filed with the SEC on Mar 21 ’25 that Bruno Julianne (Chief Operating Officer) sold a total of 1,714 shares of the company’s common stock. The trade occurred on Mar 21 ’25 and was made at $41.23 per share for $70668.0. Following the transaction, the insider now directly holds 10544.0 shares of the CRSP stock.
Still, SEC filings show that on Mar 21 ’25, Prasad Raju (Chief Financial Officer) disposed off 2,197 shares at an average price of $41.23 for $90582.0. The insider now directly holds 16,767 shares of CRISPR Therapeutics AG (CRSP).
